Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126081331 | 12608133 | 1 | I | 20160726 | 20160729 | 20160729 | EXP | GB-JNJFOC-20160725559 | JANSSEN | VIEGAS S, DONNELLY A, JONES B, NICHOLAS R, MALIK O. INFLIXIMAB FOR REFRACTORY NEUROSARCOIDOSIS. J NEUROL NEUROSURG PSYCHIATRY DEC-2012;83, SUPPL S2:A21. | 0.00 | Y | 0.00000 | 20160729 | MD | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126081331 | 12608133 | 1 | PS | INFLIXIMAB, RECOMBINANT | INFLIXIMAB | 1 | Intravenous (not otherwise specified) | A STANDARD REGIME WAS EMPLOYED ANDADMINISTERED AT WEEKS 0, 2 AND 6. FURTHER DOSES AT 8 WEEKLY | U | U | 103772 | LYOPHILIZED POWDER |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126081331 | 12608133 | 1 | Neurosarcoidosis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126081331 | 12608133 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126081331 | 12608133 | Off label use | |
| 126081331 | 12608133 | Product use issue | |
| 126081331 | 12608133 | Staphylococcal bacteraemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |